Paper: Long-Term Survivors after Stem Cell Transplantation in Multiple Myeloma: Bone Marrow Minimal Residual Disease, PET/CT and Immunological Status
Results: Twenty patients (20/160; 12.5%) were alive and in continuous CR after ASCT beyond 5 years; nine (5.7%) remained in CR for more than 10 years. In the alloSCT group, 6 out 58 patients (10.3%) were in CR beyond 5 years (3 of them for more than 10 years). Remarkably, two patients were in CR after 20 and 28 years after ASCT and alloSCT, respectively.
I'm in CR for more than six years now. Already far beyond expectations.
Reason for optimism.
Saturday, 28 November 2015
Monday, 9 November 2015
Tuesday, 3 November 2015
Sunday, 25 October 2015
Saturday, 17 October 2015
Saturday, 10 October 2015
Dr Joseph Alvarnas Considers Survivorship and Long-Term Effects of Cancer Therapy
Dr Joseph Alvarnas Considers Survivorship and Long-Term Effects of Cancer Therapy
With innovations making cancer a chronic illness for many patients, how does that change cancer care? Back when I was a hematology fellow, median survival for patients with multiple myeloma was about 3 years. So many of our patients, half of our patients, died in less than 3 years. So we didn't have issues of long-term survivorship. We didn't have issues of long-term considerations of the consequences of therapy, or the consequences of life-changing therapy-related complications, and now we do. So I think it's up to us as physicians and care providers to really carefully think through this idea of survivorship. When we take patients, even those who have been cured of their illness, many of them will still complain of fatigue, changes in concentration, changes in their ability to engage in day-to-day activities. And I think, globally, as we look at the successes of cancer, we shouldn't look at that as a stopping point. That, instead, is a starting point, and looking at this idea of survivorship and how best to tailor the resources of healthcare toward ensuring a good quality of life for all those who have survived a potentially life-threatening illness. - See more at: http://www.ajmc.com/interviews/dr-joseph-alvarnas-considers-at-survivorship-and-long-term-effects-of-cancer-therapy#sthash.A4UvenwK.dpuf
With innovations making cancer a chronic illness for many patients, how does that change cancer care? Back when I was a hematology fellow, median survival for patients with multiple myeloma was about 3 years. So many of our patients, half of our patients, died in less than 3 years. So we didn't have issues of long-term survivorship. We didn't have issues of long-term considerations of the consequences of therapy, or the consequences of life-changing therapy-related complications, and now we do. So I think it's up to us as physicians and care providers to really carefully think through this idea of survivorship. When we take patients, even those who have been cured of their illness, many of them will still complain of fatigue, changes in concentration, changes in their ability to engage in day-to-day activities. And I think, globally, as we look at the successes of cancer, we shouldn't look at that as a stopping point. That, instead, is a starting point, and looking at this idea of survivorship and how best to tailor the resources of healthcare toward ensuring a good quality of life for all those who have survived a potentially life-threatening illness. - See more at: http://www.ajmc.com/interviews/dr-joseph-alvarnas-considers-at-survivorship-and-long-term-effects-of-cancer-therapy#sthash.A4UvenwK.dpuf
Subscribe to:
Posts (Atom)